表紙
市場調查報告書

神經退化性疾病的全球市場:成長,趨勢,及預測(2019年∼2024年)

Neurodegenerative Disease Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391465
出版日期 內容資訊 英文 130 Pages
商品交期: 2-3個工作天內
價格
Back to Top
神經退化性疾病的全球市場:成長,趨勢,及預測(2019年∼2024年) Neurodegenerative Disease Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年11月01日內容資訊: 英文 130 Pages
簡介

本報告提供全球神經退化性疾病市場的相關調查,市場機會和趨勢,成長及阻礙因素,各適應症類型、藥物類型、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 神經病變的盛行率上升
    • 認識度的提高
    • 神經退化性疾病治療的強力產品平台
  • 市場阻礙因素
    • 神經退化性疾病治療產品的專利期限
    • 嚴格的法規指南
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各表示類型
    • 帕金森氏症
    • 阿茲海默症
    • 多發性硬化症
    • 亨丁頓舞蹈症
    • 其他
  • 各藥物類型
    • N-甲基-D-天冬氨酸受體
    • 選擇性血清素再吸收抑制劑
    • 多巴胺抑制劑
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • AbbVie Inc.
    • Amneal Pharmaceuticals Inc.
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline PLC
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical
    • UCB SA

第7章 市場機會及今後趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 51059

Market Overview

The major factors for the growth of the neurodegenerative disease market include the rising prevalence of neurological disorders, increasing public awareness, and strong product pipeline for neurodegenerative disease treatment.

With increasing global population and average lifespan, the prevalence of neurological disorders is on the rise, worldwide. According to a study by the Parkinson's Disease Foundation, the number of new cases of the disease has increased over the last 30 years. Globally, over 10 million people are living with Parkinson's disease, according to the statistics of 2016. The Alzheimer's Association stated that around 5.4 million people in the United States were living with Alzheimer's disease, in 2016. This disease is the sixth-leading cause of death in the United States, and is more prevalent among people above 65 years of age, as 5.2 million out of the 5.4 million patients fall in this age bracket. The increase in global average age contributes to increased prevalence of Amyotrophic Lateral Sclerosis (ALS), since the disease is most prevalent in people above 60 years of age. According to a report, approximately 4 out of 10,000 people in the United States had ALS in 2015, which is expected to increase in the coming years. At present, around 30,000 people in the United States are estimated to be suffering from Huntington's disease. The prevalence of these diseases among all races, genders, and geographical backgrounds is increasing with the rise in the world population. The aforementioned numbers suggest that the prevalence of neurodegenerative disorders is on the rise, contributing to the growth of the market over the forecast period.

Scope of the Report

As per the scope of this report, neurodegenerative disease is a broad term used to denote a range of conditions that primarily affect the neurons in the brain. Neurodegenerative diseases are incurable, and the degradation of neurons leads to the gradual death of neurons. The market is segmented by indication type, drug type, and geography.

Key Market Trends

Parkinson's Disease Segment by Indication Type is Expected to Be the Fastest Growing Segment

The initial symptoms of Parkinson's disease include shaking, rigidity, uneasiness in walking, and slowness. Anxiety and depression are very common in patients suffering from Parkinson's disease. Anti-Parkinson drugs, such as Levodopa and Carbidopa, are the most commonly administered drugs, along with dopamine agonists. Ropinirole, Pramipexole, and Rotigotine are some common dopamine agonists prescribed for the disease. Selegiline and Rasagiline are the drugs that conserve dopamine and prevent degradation. COMT inhibitors are also administered to prevent the degradation of dopamine. According to the Parkinson's Disease Foundation, nearly 10 million people worldwide are living with Parkinson's disease. The risk of Parkinson's disease increases with age. The growing aging population, especially in North America and Europe, is the primary factor propelling the growth of the market. The increasing awareness and incidences of the disease are boosting the market growth. According to the Parkinson's Disease Foundation, medication cost for a patient with the disease is on an average USD 2,500 a year, and therapeutic surgery costs nearly USD 100,000 per person. In 2017, North America accounted for the largest market, followed by Europe and Asia-Pacific.

North America is Expected to Dominate the Market

North America is the most significant region in Parkinson's drugs market. As many as one million Americans live with Parkinson's disease (PD), which is more than the combined number of people diagnosed with multiple sclerosis, muscular dystrophy, and Lou Gehrig's disease. According to Parkinson's news, 2018, approximately 1.2 million people in the United States are predicted to have Parkinson's disease by 2030. It is the second-most common neurodegenerative disorder in the United States. Also, there are thousands of patients who go undetected. As the US population continues to age, the number of people living with Parkinson disease (PD) continues to grow, and it is expected to double between 2010 and 2040. Recently, the Food and Drug Administration (FDA) approved safinamide (Xadago) tablets as an add-on treatment to levodopa/carbidopa for patients with PD, who are experiencing "off" episodes. FDA approved the drug in March 2017. On the other hand, patients are adopting the generics due to the low cost, and are further expected to restrain the patented drugs. Hence, this generic competition between the new entrants is expected to show a steady growth rate, during the forecast period.

Competitive Landscape

The market studied is a consolidated, owing to the presence of a few major market players. Some of the market players are AbbVie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim Group, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical, and UCB SA.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

TABLE OF CONTENTs

1. INTRODUCTION

  • 1.1. Study Deliverables
  • 1.2. Study Assumptions
  • 1.3. Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1. Market Overview
  • 4.2. Market Drivers
    • 4.2.1. Rising Prevalence of Neurological Disorders
    • 4.2.2. Increasing Public Awareness
    • 4.2.3. Strong Product Pipeline for Neurodegenerative Disease Treatment
  • 4.3. Market Restraints
    • 4.3.1. Patent Expiry of Neurodegenerative Disease Treatment Products
    • 4.3.2. Stringent Regulatory Guidelines
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Threat of New Entrants
    • 4.4.2. Bargaining Power of Buyers/Consumers
    • 4.4.3. Bargaining Power of Suppliers
    • 4.4.4. Threat of Substitute Products
    • 4.4.5. Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1. By Indication Type
    • 5.1.1. Parkinson's Disease
    • 5.1.2. Alzheimer's Disease
    • 5.1.3. Multiple Sclerosis
    • 5.1.4. Huntington Disease
    • 5.1.5. Other Indication Types
  • 5.2. By Drug Type
    • 5.2.1. N-methyl-D-aspartate Receptor
    • 5.2.2. Selective Serotonin Reuptake Inhibitor
    • 5.2.3. Dopamine Inhibitors
    • 5.2.4. Other Drug Types
  • 5.3. Geography
    • 5.3.1. North America
      • 5.3.1.1. United States
      • 5.3.1.2. Canada
      • 5.3.1.3. Mexico
    • 5.3.2. Europe
      • 5.3.2.1. Germany
      • 5.3.2.2. United Kingdom
      • 5.3.2.3. France
      • 5.3.2.4. Italy
      • 5.3.2.5. Spain
      • 5.3.2.6. Rest of Europe
    • 5.3.3. Asia-Pacific
      • 5.3.3.1. China
      • 5.3.3.2. Japan
      • 5.3.3.3. India
      • 5.3.3.4. Australia
      • 5.3.3.5. South Korea
      • 5.3.3.6. Rest of Asia-Pacific
    • 5.3.4. Middle East & Africa
      • 5.3.4.1. GCC
      • 5.3.4.2. South Africa
      • 5.3.4.3. Rest of Middle East & Africa
    • 5.3.5. South America
      • 5.3.5.1. Brazil
      • 5.3.5.2. Argentina
      • 5.3.5.3. Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1. Company Profiles
    • 6.1.1. AbbVie Inc.
    • 6.1.2. Amneal Pharmaceuticals Inc.
    • 6.1.3. Boehringer Ingelheim International GmbH
    • 6.1.4. F. Hoffmann-La Roche Ltd
    • 6.1.5. GlaxoSmithKline PLC
    • 6.1.6. Merck & Co. Inc.
    • 6.1.7. Pfizer Inc.
    • 6.1.8. Teva Pharmaceutical
    • 6.1.9. UCB SA

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top